Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...

For now, however, the Prevnar brand remains largely unscathed from Merck's challenge. Vaxneuvance was launched after Pfizer introduced Prevnar 20, but debuted with FDA approval for paediatric use ...

The Prevnar 20 approval comes a few weeks ahead of an FDA decision on Merck's V114, which was granted a priority review by the regulator in January for the prevention of IPD in adults.

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

Neomycin is an antibiotic that interferes with bacterial protein synthesis by binding primarily to the 30S subunit of bacterial ribosomes. Many vaccines contain trace amounts of neomycin to ...

Vaccines are responsible for the control of many infectious diseases that were once common in the United States, including polio, measles, diphtheria, pertussis (whooping cough), rubella (German ...

After hours: March 12 at 7:59:30 PM EDT Loading Chart for PFE ...